University of Witten/Herdecke   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Witten Germany (1983)

Organization Overview

First Clinical Trial
1999
NCT00209833
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Datteln University Witten-Herdecke | Department of Anesthesiology, Helios Klinikukm Wuppertal | DZNE Witten | HELIOS Clinic Wuppertal | HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation | Helios Klinikum Bad Saarow | Helios Klinikum Berlin | Helios Klinikum Berlin-Buch | HELIOS Klinikum Berlin-Buch | HELIOS Klinikum Bonn/Rhein-Sieg | Helios Klinikum Erfurt | Klinikum Wuppertal GmbH | Prof. Dr. Frank Mooren | Universität Witten/Herdecke | University of Witten/Herdecke | Witten\Herdecke University

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Airway Obstruction (Phase 2)

Anemia, Refractory (Phase 3)

Anemia, Refractory, with Excess of Blasts (Phase 3)

Dyspnea (Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Hemangiosarcoma (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Prolymphocytic (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Neoplasm Metastasis (Phase 3)

Neuralgia (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Hip (Phase 2)

Pancreatic Neoplasms (Phase 3)

Shock (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 24